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Abstract
We previously reported that nab-paclitaxel-based induction chemotherapy (IC)
and concurrent chemoradiotherapy resulted in low relapse rates (13%) and
excellent survival in head and neck squamous cell carcinoma (HNSCC). We
compare the disease-specific survival (DSS) and overall survival (OS) between
patients given nab-paclitaxel, cisplatin, and fluorouracil with cetuximab (APF-
C) and historical controls given docetaxel, cisplatin, and fluorouracil with ce-
tuximab (TPF-C). Patients with locally advanced HNSCC were treated with
APF-C (n = 30) or TPF-C (n = 38). After 3 cycles of IC, patients were sched-
uled to receive cisplatin concurrent with definitive radiotherapy. T and N clas-
sification and smoking history were similar between the two groups and within
p16-positive and p16-negative subsets. The median duration of follow-up for
living patients in the APF-C group was 43.5 (range: 30–58) months versus 52
(range: 13–84) months for TPF-C. The 2-year DSS for patients treated with
APF-C was 96.7% [95% Confidence Interval (CI): 85.2%, 99.8%] and with
TPF-C was 77.6% (CI: 62.6%, 89.7%) (P = 0.0004). Disease progression that
resulted in death was more frequent in the TPF-C group (39%) compared with
the APF-C group (3%) when adjusted for competing risks of death from other
causes (Gray’s test, P = 0.0004). In p16 positive OPSCC, the 2-year DSS for
APF-C was 100% and for TPF-C was 74.6% (CI: 47.4%, 94.6%) (P = 0.0019)
and the 2-year OS for APF-C was 94.1% (CI: 65.0%, 99.2%) and for TPF-C
was 74.6% (CI: 39.8%, 91.1%) (P = 0.013). In p16 negative HNSCC, the 2-year
DSS for APF-C was 91.7% (CI: 67.6%, 99.6%) and for TPF-C was 82.6% (CI:
64.4%, 94.8%) (P = 0.092). A 2-year DSS and OS were significantly better with
a nab-paclitaxel-based IC regimen (APF-C) compared to a docetaxel-based IC
regimen (TPF-C) in p16-positive OPSCC.
Introduction
Most patients with squamous cell carcinoma of the head
and neck (HNSCC) present with locally advanced disease
(stage III–IV), and 5-year overall survival (OS) rates with
multimodality treatment are 40–60% [1]. Induction che-
motherapy (IC) may be employed as a treatment strategy
for locally advanced HNSCC, as it has the advantages of
potential organ preservation, early identification of
patients likely to benefit from chemoradiotherapy (CRT),
and decreased incidence of distant metastases. The
most widely used IC regimen is docetaxel, cisplatin, and
ª 2014 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of
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fluorouracil (TPF), based on two randomized trials that
showed a survival benefit with docetaxel added to cis-
platin and fluorouracil (PF) [2, 3].
Nab-paclitaxel is a microtubule inhibitor formulated as a
colloidal suspension of paclitaxel and human serum albu-
min. Preclinical studies suggest that albumin binding to cell
surface receptors can facilitate transport of nab-paclitaxel
into tumor cells [4]. We recently published results of a
prospective phase 2 trial investigating a novel induction
regimen of nab-paclitaxel, cisplatin, and fluorouracil with
cetuximab (APF-C), followed by CRT [5]. Survival
outcomes in patients treated with APF-C followed by CRT
were very favorable, with a relapse rate of only 13%.
We hypothesized that a nab-paclitaxel-based compared
to a docetaxel-based IC regimen would be better in terms
of survival endpoints. We compared survival outcomes of
patients treated with APF-C to institutional historical
controls who received TPF plus cetuximab (TPF-C). Both




All patient data were collected through an institutional
review board (IRB)-approved retrospective analysis.
Patients treated with APF-C (n = 30) were enrolled
onto an IRB-approved prospective phase 2 trial at our
institution between 2009 and 2010 (clinicaltrials .gov
NCT00736944). The results of this trial were published,
but were updated for this analysis [5]. The historical
comparison group consisted of patients who received IC
with TPF-C (n = 38) and were enrolled onto an IRB-
approved head and neck registry between 2006 and 2010.
Eligibility criteria for both IC groups included untreated
Stage III and IVa/b HNSCC, Eastern Cooperative Oncol-
ogy Group (ECOG) performance status of 0–1, T2–4 clas-
sification, and plan to receive three cycles of IC followed
by cisplatin concurrent with definitive RT.
Treatment regimens
Induction chemotherapy
The APF-C group was treated with every 3-week cycles of
IV nab-paclitaxel 100 mg/m2 on days 1, 8, and 15, cis-
platin 75 mg/m2 on day 1, 5-FU 750 mg/m2 continuous
IV infusion (CIVI) daily on days 1–3, and cetuximab
400 mg/m2 day 1 and 250 mg/m2 weekly subsequently
[5]. The TPF-C group was treated with every 3-week
cycles of docetaxel 75 mg/m2 and cisplatin 75 mg/m2 on
day 1, 5-FU 750 mg/m2 CIVI daily on days 1–3, and
cetuximab 400 mg/m2 day 1 and 250 mg/m2 weekly subse-
quently. Three cycles of IC were planned for both groups.
Definition of primary tumor site response criteria
Response at the primary tumor site was determined by
visual analysis by the otolaryngologist after 2 cycles of IC.
Response was categorized as complete response (CR:
complete resolution of the primary tumor), partial
response (PR: greater than 50% decrease but less than
CR), stable disease (SD: 0–49% decrease) or progressive
disease (PD: any increase), as previously described [5].
Patients with favorable response (CR/PR) at the primary
site proceeded to CRT after cycle 3 of IC. Surgical inter-
vention was considered in patients with an unfavorable
(SD/PD) tumor response at the primary site.
Chemoradiotherapy
CRT was started after the final cycle of IC. Intensity-mod-
ulated radiation therapy (IMRT) was administered once
daily, 5 days weekly, as previously described [5]. The
APF-C and TPF-C groups received cisplatin 100 mg/m2
on day 1, 22, and 43 if creatinine <2.0 (if not, cetuximab
was administered, as previously described) [5].
Standard assessments
Baseline assessments included history and physical exami-
nation, laryngoscopy, computed tomography (CT) of the
neck, and F-18 fluorodeoxyglucose positron emission
tomography/CT (FDG-PET/CT). Assessments of adverse
events (AEs) were performed using National Cancer Insti-
tute–Common Toxicity Criteria (NCI-CTC) version 3.0.
After two cycles of IC, patients underwent assessment of
tumor response by clinical examination and CT neck [5].
Subsequent follow-up was performed as previously
reported [5]. Comorbidities were quantified using the
Adult Comorbidity Evaluation (ACE)-27 index [6].
p16
Immunohistochemistry for p16, a surrogate for human
papillomavirus (HPV), was performed on oropharyngeal
(OP) tumors, as previously described [7] and was scored
by the pathologist (JSL) as positive when ≥50% of tumor
cells showed nuclear and cytoplasmic staining.
Statistical methods
Demographic and disease characteristics of the patients
were summarized using descriptive statistics. Treatment
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differences regarding response rates at the primary tumor
site were examined using Cochran–Mantel–Haenszel, and
Fisher’s exact test for unordered or fewer than 3 catego-
ries and Jonckheere tests for ordinal trend for 3 or more
categories. Disease-specific survival (DSS) was estimated
by the cumulative incidence method to account for com-
peting risks of death due to treatment-related or other
causes. Cox proportional hazards models were used to
estimate cause-specific hazards.
OS was defined as time from diagnosis to death or to
last follow-up alive. Progression-free survival (PFS) was
defined as time from diagnosis to death due to disease
progression, to disease progression, or to last follow-up
alive. DSS was defined as time from diagnosis to death
from disease or to last follow-up alive.
Results
Patient and tumor characteristics
A number 68 patients were included in this analysis: 30
in the APF-C group and 38 in the TPF-C group. Baseline
characteristics including T&N classification, smoking his-
tory, and primary tumor site were similar between the
two groups (Table 1). A larger proportion of patients in
the APF-C group (57%) had p16-positive OPSCC in
comparison to the TPF-C group (34.1%) (P = 0.068).
Therefore, survival outcome analyses were stratified for
this important prognostic variable. Importantly, in either
the p16-positive or p16-negative subsets, there were no
significant differences in the proportions of patients who
Table 1. Patient and tumor characteristics.
APF-C (n = 30) TPF-C (n = 38)
P value
No. % No. %
Characteristic
Age (years)
Median 57 55 0.952
Range 38–71 38–72
Sex
Male 28 93 34 90 0.693
Female 2 7 4 10
Smoking history
Yes 27 90 35 92 0.993
No 3 10 3 8
ACE comorbidity index
0 (none) 9 30 9 24 0.124
1 (mild) 2 7 17 45
2 (moderate) 13 43 9 24
3 (severe) 6 20 3 8
Primary site
Oropharynx 22 73 25 66 0.573
Larynx 7 23 12 32
Hypopharynx 0 0 1 3
Oral cavity 1 3 0 0
T classification
T2 8 27 5 13 0.274
T3 11 37 16 42
T4 11 37 17 45
N classification
N0 and N1 6 20 10 26 0.834
N2a/b 6 20 9 24
N2c 14 47 10 26
N3 4 13 9 24
p16 positive
Oropharynx1 17 57 13 34 0.0683
1Two patients with oropharynx HNSCC did not have p16 staining performed and are not included in these data. Overall, there were 47 patients
with oropharynx tumors, 30 of whom were p16 positive and were included here.
2P-value from a t-test.
3Fisher’s exact test.
4Jonckheere–Terpstra test (for trend over an ordinal variable).
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smoked, who had T2, T3, or T4 classification, or who
had N0/1, N2 or N3 classification in the APF-C compared
to the TPF-C groups (data not shown).
Treatment delivery
Treatment delivery details are described in Table 2. Here
100% of the APF-C and the TPF-C groups completed 2
or more IC cycles, 97% of APF-C, and 84% of TPF-C
patients received 3 IC cycles.
Twenty-nine of 30 (96.7%) patients given APF-C and 34
of 38 (89.5%) patients given TPF-C received IMRT. Rea-
sons that patients did not receive IMRT included treat-
ment-related mortality (TRM) during IC (n = 2),
metastatic disease progression occurring during comorbidi-
ty-related treatment delay (n = 1), surgery following IC
with no adjuvant therapy (n = 1), and lost to follow-up
(n = 1). The IMRT delivery was similar across the two IC
groups. The majority of patients in the APF-C (93%) and
TPF-C (85%) groups received cisplatin concurrent with
IMRT. Others received cetuximab concurrent with IMRT.
Primary tumor site response after 2 cycles
of IC
The overall response rate at the primary site after 2 cycles
of IC was 100% for APF-C and 84% for TPF-C
(P = 0.031). Progressive or stable disease after 2 cycles of
TPF-C was seen in 13% (n = 5) and 3% (n = 1) of
patients, respectively. Patients treated with APF-C had a
greater risk of overall response at the primary tumor site
than those treated with TPF-C after adjusting for p16 sta-
tus (relative risk = 1.17; 95% confidence interval [CI]:
1.02–1.34).
Overall, the CR rate at the primary site was 53.3% for
APF-C compared to 34.2% for TPF-C (P = 0.14). In p16-
positive OPSCC, the CR rate at the primary tumor site
was 64.7% for APF-C and 38.5% for TPF-C (P = 0.27).
In p16 negative HNSCC, the CR rate was 33.3% for APF-
C and 33.3% for TPF-C (P = 0.99).
Neck nodal and overall tumor site response
after 2 cycles of IC
The tumor response rates at neck nodal sites after 2 cycles
of APF-C and TPF-C respectively, based on clinical exam-
inations were 61% CR (11 patients) compared to 45%
CR (13 patients) and 39% PR (7 patients) compared to
48% PR (14 patients). In the APF-C group, the neck
nodes of all patients who were evaluated responded, but
in the TPF-C group stable or progressive nodal disease
was seen in 7% (2 patients). Twelve patients in the APF-
C group and 9 patients in the TPF-C group were not
evaluable for this endpoint because of initial absence of
nodal disease on clinical examination.
The overall tumor response rates for APF-C were 43%
CR, 57% PR, and 0% SD/PD, whereas the overall tumor
response rates for TPF-C were 26% CR, 58% PR, and
16% SD/PD.
Disease-specific survival
The median duration of follow-up for living patients in
the APF-C group was 43.5 (range: 30–58) months versus
Table 2. Treatment delivery.
Treatment








<100% of total dose
Induction chemotherapy
nab-Paclitaxel 100 (67–100) 14 (47) – –
Docetaxel – – 100 (67–100) 11 (29)
Cetuximab 100 (27–100) 14 (47) 89 (0–100) 21 (57)
Cisplatin 100 (67–100) 2 (7) 100 (67–100) 8 (21)
Fluorouracil 100 (80–100) 2 (7) 100 (58–100) 14 (37)
Chemoradiotherapy 1 2
Radiation therapy n = 29 n = 34
Median dose Gy (range) 70 (14–72) 3 (10) 70 (70––72) 4 (11)
Median elapsed days (range) 50 (8–69) 50 (37–64)
Concurrent chemotherapy n = 28 n = 34
Cisplatin (% patients) 27 (93) 29 (85)
% Total dose (range) 76 (33–100) 17 (57) 71 (33–100) 27 (71)
Cetuximab (% patients) 1 (4) 5 (15)
1Denominator is 30 patients.
2Denominator is 38 patients.
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52 (range: 13–84) months for TPF-C. All but 4 of the liv-
ing patients had a minimum of 2 years of follow-up.
Two-year DSS was 96.7% (CI: 85.2%, 99.8%) for
patients given APF-C compared to 77.6% (CI: 62.6%,
89.7%) for patients given TPF-C (P = 0.0004) (Fig. 1A).
Table 3 displays the univariate analysis of proportions of
treatment failures due to disease for patient, tumor, and
treatment characteristics. Given the prognostic signifi-
cance of HPV in HNSCC [8], we stratified DSS for p16
status and treatment group. The 2-year DSS of patients
with p16-positive OPSCC was 100% for APF-C (n = 17)
and 74.6% (CI: 47.4%, 94.6%) for TPF-C (n = 13)
(P = 0.0019) (Fig. 1B). Two-year DSS of patients with
p16 negative HNSCC was 91.7% (CI: 67.6%, 99.6%) for
APF-C (n = 12) versus 82.6% (CI: 64.4%, 94.8%) for
TPF-C (n = 24) (P = 0.092).
Progression-free and overall survival
Overall, 2-year PFS was 89.3% for APF-C and 55.7% for
TPF-C (P = 0.0019) (Fig. 1C). Two-year PFS for patients
with p16-positive OPSCC was 93.8% for APF-C and
68.4% for TPF-C (P = 0.034). The 2-year PFS for patients
with p16 negative HNSCC was 81.8% for APF-C, and
51.2% with TPF-C (P = 0.091).
Overall, 2-year OS was 90.0% for APF-C and 66.6%
for TPF-C (P = 0.0008) (Fig. 1D). The 2-year OS for
patients with p16-positive OPSCC was 94.1% for APF-C
and 74.6% for TPF-C (P = 0.013). The 2-year OS for
patients with p16 negative HNSCC was 83.3% for APF-C
and 65.4% for TPF-C (P = 0.088).
Causes of death
Causes of death are shown in Table 4. Disease progression
resulting in death was more common in the TPF-C group
(39%) compared to the APF-C group (3%). A competing
risks model (Gray’s test) [9] was used to differentiate
deaths due to disease progression from other causes of
death without censoring deaths of other causes. This
model showed that the incidence of death due to disease
progression was greater in the TPF-C group compared to
the APF-C group (P = 0.0004). The hazard of death due
to disease progression is 94% lower in the APF-C group
than in the TPF-C group (HR = 0.060 [CI: 0.008, 0.45]).
There was no difference in the hazard ratios of TRM or
A B
C D
Figure 1. Survival outcomes in the APF-C and TPF-C groups. (A) DSS, (B) DSS by p16 status and treatment group, (C) PFS, (D) OS.
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death of other causes (second malignancy and noncancer
death) in the two treatment groups (TRM:HR = 0.632
[CI: 0.057, 6.97]); death of other causes [HR = 0.701 (CI:
0.116, 4.24)] (Fig. 2).
Site of relapse and salvage surgery
Four patients (13%) in the APF-C group developed
relapse (3 local/regional, 1 distant). In the TPF-C group,
17 patients (45%) developed relapse (8 local/regional, 5
distant, 4 both).
An unfavorable response to IC occurred in 6 patients
(5 PD;1 SD); one of these patients underwent salvage sur-
gery and 5 proceeded to CRT (patient/physician prefer-
ence or not surgical candidate). Following CRT, 1 patient
in the APF-C group underwent a neck dissection for a
residual neck mass and the pathology was negative for
malignancy. In the TPF-C group, 1 patient underwent
post-treatment resection of residual malignancy.
Adverse events
Table 4 summarizes the AEs related to treatment during
IC and CRT. Neuropathy and creatinine elevation
were more frequent with APF-C, although most were
grade 1–2.
Discussion
This study is a historical comparison of survival outcomes
of different taxane-based IC regimens in HNSCC. Patients
treated with the nab-paclitaxel-based IC regimen (APF-C)
followed by CRT had better 2-year DSS and OS and a
lower hazard of death due to disease progression com-
pared to the docetaxel-based regimen (TPF-C) followed by
CRT. T and N classifications and smoking history were
balanced between the two treatment groups and within
p16-positive and p16-negative subsets. Differences in the
proportion of patients with p16-positive tumors existed,
favoring better outcomes in the APF-C group. However, it
was within the p16-positive OPSCC subset that we
observed significantly better 2-year DSS and OS with APF-
C compared to TPF-C (DSS: 100% vs. 74.6%, P = 0.0019
and OS: 94.1% vs. 74.6%, P = 0.013, respectively).
Relapse of disease was more frequent in the TPF-C
group compared to the APF-C group (Kaplan–Meier esti-
mate 51.8% vs. 16%, respectively at 41 months). Given
the mix of p16 negative HNSCC and p16-positive OPSCC
patients, both of which were enriched for smoking history
and bulky disease, the risk of relapse of disease was very
low with APF-C. In the TAX 324 and Paradigm trials,
relapse of disease occurred in 56% and 24% of patients
given TPF followed by CRT, respectively [3, 10, 11]. The
higher risk of relapse of disease observed with TPF-C in
comparison to TPF in the Paradigm trial may reflect the
greater proportion of patients with T3/4 and N2c/3 classi-
fication in our study.
The 2-year PFS and OS were 89.3%, and 90%, respec-
tively, for all patients treated with APF-C. Recognizing
the potential pitfalls of cross-study comparisons, these
findings compare very favorably to contemporary studies
of TPF followed by CRT, with 2 or 3-year PFS rates of
54-67% and 2 or 3-year OS rates of 67–73% [10, 11].
Absolute PFS and OS with APF-C were better than with
TPF in the TAX 324 trial in p16 negative HNSCC (2-year
PFS 75% and 35%, respectively; 2-year OS 83.3% and
48%, respectively) and p16-positive OPSCC (2-year PFS
88.2% and 83%, respectively; 2-year OS 94% and 89%,
respectively) [11]. Cetuximab has been incorporated into
docetaxel-containing IC, with 3-year PFS and OS of 70%
and 74%, respectively [12].
Two questions arise about the relative contributions
of components of APF-C. Is nab-paclitaxel better than





















T4 10/28 0.46 (T3 vs. T2)
0.095 (T4 vs. T2)T3 5/27
T2 1/13
N classification
N3 7/13 0.46 (N2 vs. N0/N1)












486 ª 2014 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Nabpaclitaxel-Based Versus Docetaxel-Based IC in SCCHN A. Schell et al.
cremophor-based paclitaxel in HNSCC and is there a
role for cetuximab in IC? A comparison of cremophor-
based paclitaxel and PF to PF showed no significant
difference in 2-year OS (66.5% vs. 53.6%, respectively)
[13]. Although cross-study comparisons have limitations,
the 2-year OS (90%) results with APF-C compare more
favorably than these data. SPARC (secreted protein acidic
and rich in cysteine) plays a role in albumin receptor-
mediated endothelial transport [14]. SPARC expression is
common in tumor and stromal cells of HNSCC but not
in adjacent normal oral mucosa [15], and correlated with
tumor response to nab-paclitaxel in HNSCC in one study
[4]. Macropinocytosis, the process by which macromole-
cules like albumin are taken up into cells, is upregulated
in the setting of activated RAS or PI3K pathways [16].
RAS and/or components of the PI3K pathways are fre-
quently activated in HNSCC [17–22], in particular p16-
positive OPSCC, and could explain the high anti-tumor
effect of nab-paclitaxel in HNSCC. Collectively, these data
suggest but do not prove that nab-paclitaxel may be bet-
ter than cremophor-based paclitaxel in HNSCC.
With respect to the second question, the EXTREME
trial showed that the addition of cetuximab to chemo-
therapy improved tumor response rates and OS in
patients with incurable HNSCC [23]. Therefore, we antic-
ipated an improvement in tumor response rates at the
primary tumor site and 2-year survival outcomes with the
addition of cetuximab to TPF and to APF. However, our
trial was not designed to assess this hypothesis. We are
prospectively evaluating nab-paclitaxel, cisplatin, and
5-fluorouracil (APF) without cetuximab as IC before CRT
for HNSCC (NCT01566435) and plan to compare out-
comes with the APF-C regimen.
IC is a controversial therapeutic strategy in HNSCC.
While a few trials had shown an OS benefit with this
approach [24, 25], other trials have not confirmed this. The
two largest trials evaluating the role of IC with CRT were
the PARADIGM and DeCIDE trials [10, 26]. Both studies
randomized patients to CRT alone or TPF followed by
CRT. Neither trial reached its target accrual or showed an
OS benefit with TPF. Both trials were limited by the fact
that the preplanned 3-year OS was 50–55%; however, the
actual OS was higher (73% and 75%), lowering the statisti-
cal power. The DeCIDE trial did show improvements in
recurrence-free survival and distant failure rates with TPF.
Given these results, is there a justification for further
investigation of IC in HNSCC? A rational reason to
administer IC is to use the tumor response to IC as a
Table 4. Cause of death and selected adverse events occurring with IC and CRT.
APF-C and CRT (n = 30) TPF-C and CRT (n = 38)
P value2
Number of patients (%)
Cause of death
Disease progression 1 (3) 15 (39) –
Second malignancy 0 (0) 1 (3) –
Treatment-related 1 (3) 2 (5) –
Noncancer1 2 (6) 2 (5) –
Total 4 (13) 20 (53) –
Adverse event Grade 3 or 4 All grades Grade 3 or 4 All grades
Neuropathy 1 (3) 17 (57) 1 (3) 4 (11) 0.00014
Hypersensitivity 1 (3) 4 (13) 2 (5) 11 (29) 0.15
Rash 6 (20) 28 (93) 5 (13) 29 (76) 0.096
Mucositis 9 (30) 25 (83) 13 (34) 26 (68) 0.26
Creatinine elevation 2 (7) 18 (60) 1 (3) 7 (18) 0.00085
1Includes bowel obstruction (n = 1) and unknown (n = 2).
2P value is for comparison of all grades of toxicities, P-values from Fisher’s Exact test.
Figure 2. Cumulative incidence of death due to disease in the APF-C
and TPF-C groups.
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method to stratify patients into higher and lower risk
groups. CR at the primary tumor site to IC is an impor-
tant predictor of long-term DFS [27]. Those patients with
a favorable response at the primary tumor site to IC
could be candidates for deintensification of definitive
therapy, and those with unfavorable response to IC may
benefit from standard intensive therapy. This approach
could substantially decrease the toxicity for lower risk
patients. ECOG 1308 is a phase 2 trial investigating this
novel reason to administer IC [28]. In our study, the CR
rate at the primary tumor site in p16-positive OPSCC
was 64.7% with APF-C compared to 38.5% with TPF-C.
Therefore, APF-C may be an excellent IC regimen to
employ for risk stratification in p16-positive OPSCC.
Rates of AEs in our series were similar to that pub-
lished for TPF, as well as IC regimens that incorporated
cetuximab. In a large trial of TPF, the incidence of grade
3-4 events was 65% [2]. IC regimens with cetuximab
showed rates of mucositis (77%) and rash (45%) similar
to APF-C [29]. One TRM (3%) occurred in the APF-C
group and 2 TRM (5%) in the TPF-C group. Peripheral
neuropathy and creatinine elevation were more frequent
in the APF-C group compared to the TPF-C group,
although the majority of these AEs were grades 1–2.
Our study has limitations. This study was a retrospec-
tive analysis comparing outcomes in a prospective study
with those of historical controls. The small sample size in
each group limits the power of the statistical comparisons
and the ability to control for heterogeneity in patient and
tumor characteristics. We did not assess patient-reported
quality of life in either treatment group. Also, cetuximab
was included in both induction regimens; however, the
role of cetuximab in this setting is unclear. This is a single
institution experience that will require validation across
institutions.
In conclusion, 2-year DSS and OS were significantly
better with a nab-paclitaxel-based IC regimen (APF-C)
compared to a docetaxel-based IC regimen (TPF-C) in
p16-positive OPSCC. The outcomes support further
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